IMMUNITOAI PRIVATE LIMITED

In their own words

Short introductionabout us: immunitoAI is a lifesciences (biotech) startup that leverages AI to revolutionize antibodydiscovery. Positioned to scale globally, our full stack-platform will predictthe best therapeutic antibody candidates, saving time by 60% and money by 50%,and increasing efficiency by 2X. The problem we are solving and how: Antibodies are capable of providing target specific therapies as well as highlyspecific diagnostics but the major drawback is that it takes months to years to discover new antibodies that have the specificity and sensitivity required forthese purposes. In order to tackle this problem, we are building a platformthat uses AI assisted screening and discovery at the core of its technology.The first version of our AI will identify antibodies with higher specificity& sensitivity, & reduced immunogenicity. Later, the AI will be able tosuggest novel antibody candidates that are suited for therapeutics. Our bigvision is to be a full-stack antibody therapeutics company that willmanufacture novel therapeutic antibodies, designed and discovered by our AI. Our first product imRANK, will screen and rank existing antibodies bypredicting its specificity, sensitivity & immunogenicity. Our secondproduct, imEVOLVE will suggest mutations in the antibodies that will evolvethem into 10X better versions. The operations will comprise of a dry lab - wet lab feedback loop such that thepredictions of the AI will be validated through wet-lab experiments, and theresults of the wet-lab experiments will be fed back into the AI to keeprefining it further. Stage: We have completed the ideation stage and are now in the process of developingand validating our products. The validation will be completed by early 2022 forour first product.

Written by the company on its public Startup India profile. Not verified by us.